GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Cyclically Adjusted PB Ratio

NBY (NovaBay Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of May. 10, 2025)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-10), NovaBay Pharmaceuticals's current share price is $0.564. NovaBay Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $225.43. NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, NovaBay Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 2.95. The lowest was 0.01. And the median was 0.25.

NBY's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.47
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NovaBay Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2024 was $-0.028. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $225.43 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


NovaBay Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Cyclically Adjusted PB Ratio Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.18 0.04 0.01 -

NovaBay Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 - -

Competitive Comparison of NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

NovaBay Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.564/225.43
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBay Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, NovaBay Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.028/133.1571*133.1571
=-0.028

Current CPI (Dec. 2024) = 133.1571.

NovaBay Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201503 1,074.500 99.621 1,436.215
201506 2,452.000 100.684 3,242.834
201509 113.500 100.392 150.544
201512 -1,699.333 99.792 -2,267.490
201603 -1,824.750 100.470 -2,418.408
201606 -352.429 101.688 -461.494
201609 559.833 101.861 731.838
201612 591.750 101.863 773.548
201703 363.000 102.862 469.910
201706 267.417 103.349 344.546
201709 140.923 104.136 180.197
201712 199.538 104.011 255.453
201803 633.643 105.290 801.353
201806 530.643 106.317 664.607
201809 432.786 106.507 541.079
201812 353.857 105.998 444.524
201903 80.643 107.251 100.122
201906 98.176 108.070 120.967
201909 139.190 108.329 171.091
201912 42.304 108.420 51.956
202003 -15.174 108.902 -18.554
202006 35.107 108.767 42.979
202009 408.294 109.815 495.081
202012 362.294 109.897 438.976
202103 323.029 111.754 384.894
202106 311.361 114.631 361.680
202109 253.081 115.734 291.180
202112 243.359 117.630 275.483
202203 408.024 121.301 447.905
202206 344.886 125.017 367.343
202209 249.321 125.227 265.111
202212 130.707 125.222 138.990
202303 102.017 127.348 106.671
202306 53.658 128.729 55.504
202309 27.059 129.860 27.746
202312 4.249 129.419 4.372
202403 -1.448 131.776 -1.463
202406 -0.462 132.554 -0.464
202409 0.218 133.029 0.218
202412 -0.028 133.157 -0.028

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NovaBay Pharmaceuticals  (AMEX:NBY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NovaBay Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000
Yanbin Liu director 27/F TWO EXCHANGE SQUARE, 8 CONNAUGHT PLACE, CENTRAL K3 00000